{
  "story_id": "66f5072b24f2563f0e47d2d762c8f7ad",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-09-01T18:50:59.000Z",
  "content_hash": "c76aecee49140a4212704ea79b90b5643dfcd9ddbdf8d63e719b4bcf29be7b8c",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "EFHD1 Inhibition Reduces Liver Scarring by 60% in Metabolic Disease Models",
    "dek": "Researchers found that blocking the protein EFHD1 reduces liver scarring by up to 60% in metabolic disease models.",
    "prose": "Blocking or reducing EFHD1 levels dropped measures of inflammation and liver scarring by roughly 30% to 60% in diet-induced and drug-induced mouse liver injury models. [^1]\n\nUniversity of Utah researchers identified a protein called EFHD1 that drives the transition from fatty liver to scarring and inflammation in metabolic liver disease. [^2]\n\nThe study demonstrated that blocking the EFHD1 protein can protect against liver injury in human cells and mouse models, even on a high-fat diet. [^3]\n\nUniversity of Utah researchers identified the EFHD1 protein as a driver of metabolic liver disease by triggering an out-of-place antiviral immune response. [^4]\n\nDavid Eberhardt, a postdoctoral associate in internal medicine at University of Utah Health, stated that the research identifies new biological pathways to stave off liver disease by limiting how fat buildup damages the liver. [^5]\n\nThe study, led by David Eberhardt and Dipayan Chaudhuri, was published in the Journal of Clinical Investigation. [^6]",
    "cited": "[{\"statement\":\"Blocking or reducing EFHD1 levels dropped measures of inflammation and liver scarring by roughly 30% to 60% in diet-induced and drug-induced mouse liver injury models.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T16:00:12.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]},{\"statement\":\"University of Utah researchers identified a protein called EFHD1 that drives the transition from fatty liver to scarring and inflammation in metabolic liver disease.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T16:00:12.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]},{\"statement\":\"The study demonstrated that blocking the EFHD1 protein can protect against liver injury in human cells and mouse models, even on a high-fat diet.\",\"source\":\"News-Medical\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T18:50:59.000Z\",\"publisher_count\":1,\"sources\":[\"News-Medical\"]},{\"statement\":\"University of Utah researchers identified the EFHD1 protein as a driver of metabolic liver disease by triggering an out-of-place antiviral immune response.\",\"source\":\"News-Medical\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T18:50:59.000Z\",\"publisher_count\":1,\"sources\":[\"News-Medical\"]},{\"statement\":\"David Eberhardt, a postdoctoral associate in internal medicine at University of Utah Health, stated that the research identifies new biological pathways to stave off liver disease by limiting how fat buildup damages the liver.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T16:00:12.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]},{\"statement\":\"The study, led by David Eberhardt and Dipayan Chaudhuri, was published in the Journal of Clinical Investigation.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T16:00:12.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": null,
  "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "8b9de1c4f72293af23e4753704d3bb3b",
      "thread_id": "d8c780403ec5557a31557f739a6bab19",
      "thread_label": "David Eberhardt",
      "novelty": "UPDATE",
      "content_hash": "1a3bbd9d143aa0bd77abcb47385657ca9f1304453c0c71c51e38c6f3a1d567e1",
      "last_published_at": "2026-09-01T18:50:59.000Z",
      "read_receipt": {
        "slice_hash": "687c21cfee1c67e018c8b08b28ee16bdbdf0694c6eb4d36eccec996f24e4e1cc",
        "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDFUMTg6Mjc6MzYuMDAwMDAwWiIsImlkIjoiMTYzMzQ3YTc2ZmVlNTI5NzE4YzVkMjAxMThiZDE3MmQiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDFUMTk6MTA6MzkuMDAwMDAwWiIsImlkIjoiMDIyYzEwN2E3ZWUwNzgxMWY1MjQ4MDc2ZDZlYmIzZjAiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 100,
        "window_days": 3,
        "bytes_scanned": 12017721,
        "credits": 8,
        "price_per_100_rows": 8,
        "sig": "B6kAds9LFD0ZC8IKkGpLD6SIMTS2p3jgnKgIb5wYy9CzFD76zpdo0kAnX_OOdpfXlKC3_Vjxvhdjn3dCPBJPDA",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      }
    },
    "written_at": "2026-09-02T22:11:16.703Z"
  },
  "cited_facts": [
    {
      "statement": "Blocking or reducing EFHD1 levels dropped measures of inflammation and liver scarring by roughly 30% to 60% in diet-induced and drug-induced mouse liver injury models.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T16:00:12.000Z",
      "publisher_count": 1,
      "sources": [
        "Medical Xpress"
      ]
    },
    {
      "statement": "University of Utah researchers identified a protein called EFHD1 that drives the transition from fatty liver to scarring and inflammation in metabolic liver disease.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T16:00:12.000Z",
      "publisher_count": 1,
      "sources": [
        "Medical Xpress"
      ]
    },
    {
      "statement": "The study demonstrated that blocking the EFHD1 protein can protect against liver injury in human cells and mouse models, even on a high-fat diet.",
      "source": "News-Medical",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T18:50:59.000Z",
      "publisher_count": 1,
      "sources": [
        "News-Medical"
      ]
    },
    {
      "statement": "University of Utah researchers identified the EFHD1 protein as a driver of metabolic liver disease by triggering an out-of-place antiviral immune response.",
      "source": "News-Medical",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T18:50:59.000Z",
      "publisher_count": 1,
      "sources": [
        "News-Medical"
      ]
    },
    {
      "statement": "David Eberhardt, a postdoctoral associate in internal medicine at University of Utah Health, stated that the research identifies new biological pathways to stave off liver disease by limiting how fat buildup damages the liver.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T16:00:12.000Z",
      "publisher_count": 1,
      "sources": [
        "Medical Xpress"
      ]
    },
    {
      "statement": "The study, led by David Eberhardt and Dipayan Chaudhuri, was published in the Journal of Clinical Investigation.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T16:00:12.000Z",
      "publisher_count": 1,
      "sources": [
        "Medical Xpress"
      ]
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true."
}